The STRIDE regimen, involving dual blockade of PD-L1 and CTLA-4, significantly enhanced antitumor immunity, as evidenced by extensive tumor necrosis and lymphoplasmacytic infiltration. This evidence concerns the gene CTLA4 and neoplasm.